Applicant, as named in the Orange Book

Gilead Sciences Inc

Next listed expiry: Sovaldi on 11 Jun 2031. 23 products with live protection, 2 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Sovaldi · 2 strengths sofosbuvir	sofosbuvir	204671	11 Jun 2031	patent
Sovaldi · 2 strengths sofosbuvir	sofosbuvir	212480	11 Jun 2031	patent
Complera emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	202123	14 Jan 2033	patent
Odefsey emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	208351	15 Feb 2033	patent
Vemlidy tenofovir alafenamide fumarate	tenofovir alafenamide fumarate	208464	15 Feb 2033	patent
Harvoni · 2 strengths ledipasvir; sofosbuvir	ledipasvir; sofosbuvir	212477	14 Mar 2033	patent
Genvoya cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	207561	6 Apr 2033	patent
Stribild cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	203100	6 Apr 2033	patent
Zydelig · 2 strengths idelalisib	idelalisib	205858	2 Sep 2033	patent
Epclusa · 2 strengths sofosbuvir; velpatasvir	sofosbuvir; velpatasvir	214187	30 Jul 2034	patent
Epclusa · 2 strengths sofosbuvir; velpatasvir	sofosbuvir; velpatasvir	208341	30 Jul 2034	patent
Harvoni · 2 strengths ledipasvir; sofosbuvir	ledipasvir; sofosbuvir	205834	30 Jul 2034	patent
Descovy · 2 strengths emtricitabine; tenofovir alafenamide fumarate	emtricitabine; tenofovir alafenamide fumarate	208215	29 Jun 2036	patent
Biktarvy · 2 strengths bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	210251	8 Nov 2036	patent
Vosevi sofosbuvir; velpatasvir; voxilaprevir	sofosbuvir; velpatasvir; voxilaprevir	209195	1 Dec 2037	patent
Livdelzi seladelpar lysine	seladelpar lysine	217899	13 Mar 2038	patent, carve-out possible
Bixlenvo bictegravir sodium; lenacapavir sodium	bictegravir sodium; lenacapavir sodium	221104	16 Aug 2038	patent
Bixlenvo Sunlenca Starter Pack (Copackaged) bictegravir sodium, lenacapavir sodium; lenacapavir sodium	bictegravir sodium, lenacapavir sodium; lenacapavir sodium	221443	16 Aug 2038	patent
Yeztugo lenacapavir sodium	lenacapavir sodium	220020	16 Aug 2038	patent
Yeztugo lenacapavir sodium	lenacapavir sodium	220018	25 Nov 2040	patent, carve-out possible
Sunlenca lenacapavir sodium	lenacapavir sodium	215974	28 Aug 2041	patent, carve-out possible
Sunlenca lenacapavir sodium	lenacapavir sodium	215973	28 Aug 2041	patent, carve-out possible
Veklury remdesivir	remdesivir	214787	28 Nov 2041	patent

Recent events

25 Oct 2026Descovy · Generic approved 7 Apr 2026
25 Oct 2026Descovy · Generic approved 26 Aug 2026
25 Oct 2026Viread · Generic approved 18 Dec 2025
25 Oct 2026Odefsey · First generic approved 30 Jan 2026
25 Oct 2026Odefsey · Generic approved 30 Jan 2026
25 Oct 2026Vemlidy · Generic tentatively approved 9 Jul 2026
25 Oct 2026Complera · Generic approved 4 Mar 2026
25 Oct 2026Zydelig · First generic approved 17 Feb 2026
25 Oct 2026Zydelig · Generic approved 17 Feb 2026
24 Oct 2026Vitekta · Enters 12-month window basis: patent26 Apr 2027
24 Oct 2026Vitekta · Enters 12-month window basis: patent26 Apr 2027
24 Oct 2026Veklury · Exclusivity expires within 90 days PED13 Jan 2027
24 Oct 2026Veklury · Exclusivity expires within 90 days PED13 Jan 2027

Products without listed protection (2)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Viread tenofovir disoproxil fumarate	tenofovir disoproxil fumarate	022577	open now	no listed protection
Viread · 4 strengths tenofovir disoproxil fumarate	tenofovir disoproxil fumarate	021356	open now	no listed protection